Member Info for B2HS2L

I wonder how this date for court hearing affects James McCarthy's 'If you look further ahead we are calling on a figure of £100 million of revenue in 5 years and just to be clear this does not include any acquisition activity. ' - Stated in the transcript of Novacyt ‘Investor Meet’ presentation 28.04.2022.

No M&A yet James Wakefield? What happened to this? -

David Allmond - 'From a business development point of view, not a day goes by now where James and I, and some of the other senior members of the team are focused on business development across the three key areas of innovation, acceleration and strategic transaction.' - which appeared in the transcript of the 2022 half year presentation.

What happened to
'We're investigating additional panels to drop in, which are already approved to see if we can even expand further into GI, and we've found now a number of strategically aligned executable opportunities for M&A coming through the funnel. I can't be more specific, but rest assured, we will not rest until we find best use of our capital for shareholder value and future growth.' - part of the transcript of the 2022 half year presentation.

James Wakefield, you are simply not providing shareholders with enough information on these subjects to
a) attract further investors,
b) Keep the present shareholders on board.

Most shareholders are staying on board because their certificates are in the bottom draw,
it's unthinkable to sell at this sp.
Your name and reputation is mud.

IMO, DA left because he didn't agree with the future vision as Wakefield saw it, and Wakefield acted.

DA left having developed most of a strategy.
Wakefield thought he had served his purposes, and swiftly deposed DA, placing JM in charge, a money man which Wakefield saw as necessary with revenue so low.
Wakefield must be thinking Carry-The-Can David Allmond will take the blame for the 2022 s**t show.

If DHSC decide they don't want to pursue the case further, and they owe £81.5 million, that could happen on any day, and only DHSC know when it's right to make that decision.
That's why I stay in, - I'm certain Novacyt will win that argument.
I'm also fairly sure no M&A until they receive the funds.
That will be the time for any R&D, because at the moment the board are hiding from a takeover under the DHSC dispute.

...the mediation route is time consuming, but I haven't heard that we are no longer going down the mediation route. At the end of the mediation process is the court, who will have all the reasons laid out why negotiations have not led to a settlement before the case got to court.

...or you could filter yourself PI100, and save everyone loads of time reading your non-posts.

ShaunP would be most interested in what has become of Microgen right now.

https://www.eurofins.com/contact-us/worldwide-interactive-map/united-kingdom/eurofins-microgen/ , the only link to Eurofins-Microgen on the net when I checked last.

As we have been advised that the company has been closed, I would not be surprised if the truth about the above link means shareholders are due an RNS on the subject.

We should be waiting on fresh news on the Full Year 2022 Trading Update to be published soon.

The fca short spreadsheet which is updated daily, contains no companies shorted less than 0.5%.

FWIW:
The term "chemotherapy without side effects" has occured in at least one previous RNS.

Results for the period ending 31 December 2019 - Wed, 6th May 2020

. pre|CISIONTM chemotherapy platform:
significant opportunity as "chemotherapy without side effects" and in novel Affimer drug-conjugates (TMACs).

Perhaps even management thought they couldn't do worse than £4.0m in H2.
Although sales activity outside of Twitter and Linkedin almost invisible, Clonit's assays on sale for use with Q instruments may have assisted.

"what they EXPECTED for fourth quarter".
Let's wait to see the reality, before venturing further.
They are so good at saying nothing, - as though it is their right to have shareholders invest in a black hole.
Perhaps a few surprises await, we live in hope.

Research and analysis - Statutory review of the Coronavirus Test Device Approvals (CTDA) process
Published 29 December 2022
Interesting (bedtime) reading for some.

https://www.gov.uk/government/publications/coronavirus-test-device-approvals-ctda-statutory-review-of-process/statutory-review-of-the-coronavirus-test-device-approvals-ctda-process

For those with an interest in CTDA process and the need for them in UK, EU, USA etc.

FWIW
"Current market
Testing has been an important tool in the response to COVID-19.
However, the public now has stronger protection against the virus through vaccinations, natural immunity, antivirals, and increased knowledge.
As a result, COVID-19 testing is likely to play a less important role moving forward, be it testing provided from the government or tests purchased privately.

Data on the number of reported COVID-19 virus tests suggests a decline in testing in the UK.
This is also reflected in the government’s commercial exercises, including the current dynamic purchasing system (DPS) for lateral flow device (LFD) and polymerase chain reaction (PCR) kits.
DPS has some aspects similar to an electronic framework agreement, but where new suppliers can join at any time. It has been established to invite applications from potential providers of LFD and PCR test kits to maintain an ongoing supply for targeted testing after the end of universal free testing.

There has been a reduction in the number of CTDA applications, which suggests reduced demand and interest in the market. While this only shows the situation for government procured tests, it is likely indicative of the wider COVID-19 testing market. It has been difficult to accurately assess the number of SARS-CoV-2 diagnostic products on the UK market as there is no requirement for pre-market registration. However, trends in the number of applications to CTDA give some insight into the state of the market."

This may have been the last post holder:

Alison A
Title: EA to C Suite Directors at Novacyt Group.

28.10.2021 - Alison A joins Novacyt
Leaves Dec 2022.

https://www.linkedin.com/in/alisonadkinsea/?originalSubdomain=uk

Wilson
Present distributor in Cagliari = https://www.microtec-s.com/copia-di-prodotti , so I assume they visited these guys.

Muck 165 "what was there in the RNS that might explain the delay in its release?"

Just as likely Muck was what was NOT in the RNS.

I can imagine many wanting stuff IN and also kept OUT of the RNS.

bullraider

Vet diagnostics catalogue, further catalogues at foot of first screen.

https://issuu.com/primerdesign/docs/q16_genesig_vet_issuu issued 2017.

Use the 'fullscreen' control and the use mouse wheel to amplify each page.

Press Shift F3 for search facility.

TO INFINITY VIA THE NEXT COHORT AND BEYOND

Congratutulations Alastair
......./.\
...../__.\
.....|===|
.....|..A..|
.....|..V..|
.....|..C..|
.....|..T...|
.....|..A..|
.....|......|
.....|......|
.....|......|
.....|......|
..../|#||#|\
.../.|#||#|.\
../..|#||#|..\
..|../^||^\..|
..|./.^||^.\.|
..|/..^||^..\|
.....(VVV)
......(VV)
.......(V)
........*l*
......( * )
...( % : % )
.( %%:%%)
( % % % % )
(%%%.%%)
%#%#%#%

Hit the nail on the head their EXMEX.
Immediately the dispute is settled in NCYT's favour, that's when I expect M&A to take place.
This is because despite managements word they have been looking hard for M&A opportunities, no M&A has occurred, despite the long length of time that has elapsed since it was wise to consider investing cash in M&A.
It's what they do not what they say that counts for IMO.

There is no mention of the value of the companies
1 patents (IP) or
2 'Patent Box' in calculations of the companies value thus:

ie ref
1 https://www.bloomberg.com/press-releases/2021-02-02/novacyt-s-a-launch-of-pcr-genotyping-assay-portfolio-to-detect-covid-19-variants

"Novacyt’s bioinformatics surveillance group has worked with a global network
of virologists tracking variants to identify the mutations, or Single
Nucleotide Polymorphisms (SNPs), critical to each variant. From this analysis,
Novacyt has developed and patented the SNPsig portfolio, which is one of the
first commercially available for variant detection. The first three SNPsig
assays, launched today, enable the identification of the non-variant virus and
the UK, South Africa or Brazil variants, as well as any variant carrying the
N501Y mutation."

2
From Half year 2022 results presentation:
And just finally to call out our patent ORF1a/b, and that patent covers quite an extensive amount of our business. And what it means under the UK patent box tax regime, is that tax on profits associated with this patent can benefit from a tax rate of 10% rather than 19% it will not be a cash refund. It will be an offset against future tax liabilities, which is still, of course, valuable for us. We estimate that at the moment to be around £5 million.

Anyone who thinks they aren't here daily under diff aviators dream on.
https://www.youtube.com/watch?v=zV1zK8zRCPo

Bothered Kaeren? - about as bothered as Catherine tait:
https://www.google.com/search?client=avast-a-1&q=look+at+my+face+am+i+bovvered&oq=look+at+my+face+am+I+bothered%3F&aqs=avast.2.69i57j0l6.13766j0j1&ie=UTF-8#fpstate=ive&vld=cid:90154441,vid:iaRd7TBq4Og